



Announcement Summary

---

**Entity name**

CLARITY PHARMACEUTICALS LTD

**Date of this announcement**

Wednesday December 13, 2023

**The +securities the subject of this notification are:**

+Other securities issued under an +employee incentive scheme that are not intended to be quoted on ASX

**Total number of +securities to be issued/transferred**

<b>ASX +security code</b>	<b>Security description</b>	<b>Total number of +securities to be issued/transferred</b>	<b>Issue date</b>
New class - code to be confirmed	Options expiring 24 November 2028 ex. price \$0.793	1,692,023	12/12/2023
New class - code to be confirmed	Options expiring 24 November 2028 ex. price \$0.721	1,001,946	11/12/2023

Refer to next page for full details of the announcement



Part 1 - Entity and announcement details

---

**1.1 Name of entity**

CLARITY PHARMACEUTICALS LTD

We (the entity named above) give notice of the issue, conversion or payment up of the following unquoted +securities.

**1.2 Registered number type**

ABN

**Registration number**

36143005341

**1.3 ASX issuer code**

CU6

**1.4 The announcement is**

New announcement

**1.5 Date of this announcement**

13/12/2023



Part 2 - Issue details

---

**2.1 The +securities the subject of this notification are:**

+Other securities issued under an +employee incentive scheme that are not intended to be quoted on ASX

**2.2a This notification is given in relation to an issue of +securities in a class which is not quoted on ASX and which:**

does not have an existing ASX security code ("new class")



Part 3C - number and type of +securities the subject of this notification (new class) where issue has not previously been notified to ASX in an Appendix 3B

**ASX +security code**

New class - code to be confirmed

**+Security description**

Options expiring 24 November 2028 ex. price \$0.793

**+Security type**

Options

**ISIN code**

**Date the +securities the subject of this notification were issued**

12/12/2023

**Will all the +securities issued in this class rank equally in all respects from their issue date?**

Yes

**Were any of the +securities issued to +key management personnel (KMP) or an +associate?**

Yes

**Provide details of the KMP or +associates being issued +securities.**

Name of KMP	Name of registered holder	Number of +securities
Dr Alan Taylor	Dr Alan Taylor	1,134,630
Dr Colin Biggin	Dr Colin Biggin	557,393

**Have you received confirmation from ASX that the terms of the +securities are appropriate and equitable under listing rule 6.1?**

Yes

**Please provide a URL link for a document lodged with ASX setting out the material terms of the +securities being issued.**

<https://cdn-api.markitdigital.com/apiman-gateway/ASX/asx-research/1.0/file/2924-02727966-2A1482037>  
Component A - Tenure based options set out on page 15 of Notice of AGM held on 23 November 2023.

Options Details

+Security currency	Exercise price	Expiry date
AUD - Australian Dollar	AUD 0.79300000	24/11/2028

**Details of the existing class of +security that will be issued upon exercise or conversion of this new class of company option**

Other

**Description**

Options expiring 24 November 2028 with an exercise price of \$0.793. Vesting as follows:  
 24 November 2024 - 25%  
 24 November 2025 - 25%  
 24 November 2026 - 50%

**Please provide a URL link for a document lodged with ASX detailing the terms of the +employee incentive scheme or a summary of the terms**

<https://www.claritypharmaceuticals.com/wp-content/uploads/2023/05/Clarity-Pharmaceuticals-Ltd-Prospectus.pdf>

**Any other information the entity wishes to provide about the +securities the subject of this notification**

Issue is pursuant of shareholder approval of Resolutions 4 and 5 at the AGM held on 23 November 2023.

## Issue details

**Number of +securities**

1,692,023

**ASX +security code**

New class - code to be confirmed

**+Security description**

Options expiring 24 November 2028 ex. price \$0.721

**+Security type**

Options

**ISIN code****Date the +securities the subject of this notification were issued**

11/12/2023

**Will all the +securities issued in this class rank equally in all respects from their issue date?**

Yes

**Were any of the +securities issued to +key management personnel (KMP) or an +associate?**

Yes

**Provide details of the KMP or +associates being issued +securities.**

Name of KMP	Name of registered holder	Number of +securities
Dr Alan Taylor	Dr Alan Taylor	630,351
Dr Colin Biggin	Dr Colin Biggin	371,595



Have you received confirmation from ASX that the terms of the +securities are appropriate and equitable under listing rule 6.1?

Yes

Please provide a URL link for a document lodged with ASX setting out the material terms of the +securities being issued.

<https://cdn-api.markitdigital.com/apiman-gateway/ASX/asx-research/1.0/file/2924-02727966-2A1482037>

Component B - Performance based options set out on page 16 of Notice of AGM held on 23 November 2023.

#### Options Details

+Security currency	Exercise price	Expiry date
AUD - Australian Dollar	AUD 0.72100000	24/11/2028

Details of the existing class of +security that will be issued upon exercise or conversion of this new class of company option

Other

#### Description

Options expiring 24 November 2028 with an exercise price of \$0.721. Vesting 30 June 2026 subject to the satisfaction of prescribed performance conditions.

Please provide a URL link for a document lodged with ASX detailing the terms of the +employee incentive scheme or a summary of the terms

<https://www.claritypharmaceuticals.com/wp-content/uploads/2023/05/Clarity-Pharmaceuticals-Ltd-Prospectus.pdf>

Any other information the entity wishes to provide about the +securities the subject of this notification

Issue is pursuant of shareholder approval of Resolutions 4 and 5 at the AGM held on 23 November 2023.

#### Issue details

Number of +securities

1,001,946





## Part 4 - +Securities on issue

Following the issue, conversion or payment up of the +securities the subject of this application, the +securities of the entity will comprise:

(A discrepancy in these figures compared to your own may be due to a matter of timing if there is more than one application for quotation/issuance currently with ASX for processing.)

## 4.1 Quoted +Securities (Total number of each +class of +securities quoted)

ASX +security code and description	Total number of +securities on issue
CU6 : ORDINARY FULLY PAID	262,239,789

## 4.2 Unquoted +Securities (Total number of each +class of +securities issued but not quoted on ASX)

ASX +security code and description	Total number of +securities on issue
CU6AV : OPTION EXPIRING 01-JULY-2028 EX \$0.79	2,685,383
CU6AW : OPTION EXPIRING 01-JULY-2028 EX \$0.84	60,276
CU6AO : OPTION EXPIRING 26-MAY-2027 EX \$1.40	400,000
CU6AX : OPTION EXPIRING 05-SEP-2028 EX \$1.11	83,131
CU6AP : OPTION EXPIRING 01-JUL-2027 EX \$0.508	2,671,517
CU6AT : OPTION EXPIRING 06-MAR-2028 EX \$0.97	60,000
CU6AQ : OPTION EXPIRING 12-SEP-2027 EX \$0.725	350,000
CU6AM : OPTION EXPIRING 18-DEC-2024 EX \$0.83	6,600,000
CU6AN : OPTION EXPIRING 10-MAY-2026 EX \$0.94	5,560,000
CU6AL : OPTION EXPIRING 01-DEC-2024 EX \$0.61	4,300,000
CU6AR : OPTION EXPIRING 24-NOV-2027 EX \$0.508	1,921,081
CU6AS : OPTION EXPIRING 14-NOV-2027 EX \$1.06	161,771
CU6AU : OPTION EXPIRING 01-MAY-2028 EX \$0.845	96,313





New class - code to be confirmed : Options expiring 24 November 2028 ex. price \$0.793	1,692,023
New class - code to be confirmed : Options expiring 24 November 2028 ex. price \$0.721	1,001,946



Part 5 - Other Listing Rule requirements

---

**5.1 Were the +securities issued under an exception in Listing Rule 7.2 and therefore the issue did not need any security holder approval under Listing Rule 7.1?**

Yes

**5.1a Select the number of the applicable exception in Listing Rule 7.2**

14